| Literature DB >> 30691327 |
Nikola Plenagl1, Lili Duse1, Benjamin Sebastian Seitz1, Nathalie Goergen1, Shashank Reddy Pinnapireddy1, Jarmila Jedelska1, Jana Brüßler1, Udo Bakowsky1.
Abstract
Photodynamic therapy (PDT) is an established noninvasive tumor treatment. The hydrophobic natural occurring pigment hypericin shows a lot of attractive properties for the application in PDT. Hence, the administration to biological systems or patients requires the formulation in drug carriers enabling sufficient bioavailability. Therefore, free hypericin was encapsulated by the thin film hydration method or a hypericin-hydroxypropyl-β-cyclodextrin inclusion complex (Hyp-HPβCD) was incorporated by dehydration-rehydration vesicle method in either conventional or ultra-stable tetraether lipid (TEL) liposomes. The hydrodynamic diameter of the prepared nanoformulations ranged between 127 and 212 nm. These results were confirmed by atomic force microscopy. All liposomes showed a good stability under physiological conditions. TEL liposomes which tend to build more rigid bilayers, generate higher encapsulation efficiencies than their conventional counterparts. Furthermore, the suitability for intravenous application was confirmed by hemocompatibility studies resulting in a hemolytic potential less than 20% and a coagulation time less than 50 sec. The uptake of liposomal hypericin into human ovarian carcinoma cells (SK-OV-3) was confirmed using confocal microscopy and further characterized by pathway studies. It was demonstrated that the lipid composition and intraliposomal hypericin localization influenced the anti-vascular effect in the chorioallantoic membrane (CAM). While hypericin TEL liposomes exhibit substantial destruction of the microvasculature drug-in-cyclodextrin TEL liposomes showed no effect. Nevertheless, both formulations yielded severe photocytotoxicity in SK-OV-3 cells in a therapeutic dosage range. Conclusively, hypericin TEL liposomes would be perfectly suited for anti-vascular targeting while Hyp-HPβCD TEL liposomes could deliver the photosensitizer to the tumor site in a more protected manner.Entities:
Keywords: Antitumor; antiangiogenic; hypericin; liposomes; photodynamic therapy
Mesh:
Substances:
Year: 2019 PMID: 30691327 PMCID: PMC6352941 DOI: 10.1080/10717544.2018.1531954
Source DB: PubMed Journal: Drug Deliv ISSN: 1071-7544 Impact factor: 6.419
Scheme 1.Preparation of an inclusion complex (Hyp-HPβCD) consisting of hypericin and hydroxypropyl-β-cyclodextrin (HPβCD). Empty liposomes are loaded with either hypericin which associates with the hydrophobic tails in the lipid membrane or with Hyp-HPβCD incorporated in the aqueous compartment of liposomes.
Figure 1.Visualization of liposomes by AFM. Images shown on the left side are displayed in amplitude mode while the middle row shows images in measured height mode for which a cross-sectional profile along the identified lines is presented.
Hydrodynamic diameter, polydispersity index (PDI), zeta potential and entrapment efficiency (EE) [%] of hypericin liposomes. Hydrodynamic diameter is expressed as a measure of particle size distribution by intensity, n = 3.
| Lipid composition | Diameter ± SD [nm] | PDI | Zeta potential ± SD [mV] | Theoretical load [µg/ml] | Practical load [µg/ml] | EE [%] |
|---|---|---|---|---|---|---|
| DSPC/Hyp | 150 ± 11 | 0.26 | –1 ± 1 | 150 | 50.5 ± 6.2 | 33.6 ± 4.1 |
| DSPC/Hyp-HPβCD | 169 ± 10 | 0.26 | –22 ± 1 | 200 | 129.6 ± 7.8 | 64.8 ± 3.9 |
| DPPC/TEL/Hyp | 127 ± 14 | 0.24 | –2 | 150 | 123.8 ± 4.2 | 82.5 ± 2.8 |
| DPPC/TEL/Hyp-HPβCD | 212 ± 13 | 0.29 | –56 ± 1 | 200 | 163.2 ± 6.4 | 81.6 ± 3.2 |
Stability of hypericin liposomes incubated in IMDM (IMDM:liposomes/10:1 [v/v]). Hydrodynamic diameter is expressed as a measure of particle size distribution by intensity, n = 3.
| Formulation | Time [h] | Diameter ± SD [nm] | PDI ± SD | Zeta potential ± SD [mV] |
|---|---|---|---|---|
| DSPC/Hyp | 0 | 297 | 0.34 ± 0.03 | –4.4 ± 1 |
| DSPC/Hyp-HPβCD | 1 | 346 ± 10 | 0.46 ± 0.04 | –4.3 ± 1 |
| 24 | 239 ± 21 | 0.41 ± 0.04 | –3.6 ± 1 | |
| 0 | 409 ± 13 | 0.42 ± 0.02 | –6.5 ± 1 | |
| 1 | 520 ± 15 | 0.48 ± 0.03 | –7.2 ± 1 | |
| 24 | 473 | 0.43 | –6.8 ± 1 | |
| DPPC/TEL/Hyp | 0 | 235 ± 14 | 0.35 ± 0.09 | –8.5 ± 1 |
| 1 | 237 | 0.37 ± 0.08 | –9.2 ± 1 | |
| 24 | 366 ± 28 | 0.53 ± 0.06 | –10.1 ± 1 | |
| DPPC/TEL/Hyp-HPβCD | 0 | 232 ± 31 | 0.48 ± 0.03 | −13.8 ± 1 |
| 1 | 204 ± 20 | 0.54 ± 0.05 | –16.3 ± 1 | |
| 24 | 268 ± 36 | 0.45 ± 0.04 | –15.6 ± 1 |
Figure 2.(A) CLSM images of SK-OV-3 cells incubated with Hyp-HPβCD or liposomes consisting of DSPC or DPPC/TEL (90/10 mol:mol) encapsulating either hypericin or Hyp-HPβCD inclusion complex in a final concentration of 1 µM (B) SK-OV-3 cells incubated with different concentrations of free Hyp-HPβCD inclusion complex or liposomes. Incubation time was 4 h and the cells were irradiated with different light fluences of 2.1 J/cm2 (B1), 4.1 J/cm2 (B2), 8.3 J/cm2 (B3) and 12.4 J/cm2 (B4). B5 shows the influence of the incubation time (1, 2 and 4 h) on photocytotoxicity of hypericin nanoformulations with a final concentration of 250 nM hypericin and a radiation fluence of 8.3 J/cm2.
Figure 4.Tabular display of the devastation of CAM microvasculature after intravenous injection of 100 µl liposomes consisting of DSPC or DPPC/TEL (90/10 mol:mol) encapsulating either hypericin or Hyp-HPβCD inclusion complex in a total concentration of 100 µM before irradiation (t0), shortly after irradiation (t1) and 60 min after irradiation (t60) with a low level laser of 589 nm at an irradiation fluence of 11.4 J/cm2.
Figure 3.(A) Cell viability of SK-OV-3 cells after incubation with medium (Blank) or different liposomal formulations (250 nM hypericin) for 3 h and irradiation at 8.3 J/cm2. The endocytotic pathway was unhampered (no inhibition) or inhibited by Filipin III or Chlorpromazine. For statistical analysis, the results were compared against the ‘no inhibition’ value. (B) Hemolysis assay of the different liposomal formulations. Triton™ X-100 was used as positive control. (C) aPTT test of the different liposomal formulations. Blood plasma was used as control. All samples were measured in triplicates and results are expressed as the mean ± SD (n = 3) For statistical analysis, the results were compared against the results of not inhibited cells, blood cells, and fresh blood plasma respectively.